QDEL - QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 Results Terminated CEO & Withdrew FDA Submission Should Contact Hagens Berman Before June 11 2024 Deadline | Benzinga
SAN FRANCISCO, June 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ:QDEL) investors who suffered substantial losses to submit your losses now.
Class Period: Feb. 18, 2022 – Apr. 1, 2024
Lead Plaintiff Deadline: June 11, 2024
Visit: www.hbsslaw.com/investor-fraud/QDEL
Contact the Firm Now: QDEL@hbsslaw.com
844-916-0895
QuidelOrtho Corporation (NASDAQ:QDEL) Securities Class Action:
The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track."
On Apr. 2, 2024, the price of QuidelOrtho shares fell $4.85 (10%) after the company announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations. This price drop occurred after a series of disastrous revelations culminating in the filing of a securities class action on behalf of ...
QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 Results, Terminated CEO, & Withdrew FDA Submission Should Contact Hagens Berman Before June 11, 2024 Deadline>Full story available on Benzinga.com